Peddock Capital Advisors LLC lowered its holdings in shares of PerkinElmer, Inc. (NYSE:PKI) by 25.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,149 shares of the medical research company’s stock after selling 716 shares during the period. Peddock Capital Advisors LLC’s holdings in PerkinElmer were worth $209,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PKI. BlackRock Inc. increased its holdings in PerkinElmer by 10.8% in the 2nd quarter. BlackRock Inc. now owns 7,400,482 shares of the medical research company’s stock worth $712,962,000 after purchasing an additional 721,797 shares in the last quarter. Select Equity Group L.P. increased its holdings in PerkinElmer by 3.0% in the 3rd quarter. Select Equity Group L.P. now owns 7,148,794 shares of the medical research company’s stock worth $608,863,000 after purchasing an additional 205,849 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in PerkinElmer by 6.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 4,457,732 shares of the medical research company’s stock worth $379,665,000 after purchasing an additional 272,310 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in PerkinElmer by 33,237.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 793,435 shares of the medical research company’s stock worth $76,439,000 after purchasing an additional 791,055 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its holdings in PerkinElmer by 11.8% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 582,920 shares of the medical research company’s stock worth $49,647,000 after purchasing an additional 61,611 shares in the last quarter. 95.74% of the stock is owned by institutional investors.

A number of equities research analysts have commented on PKI shares. Needham & Company LLC started coverage on PerkinElmer in a research report on Friday, January 3rd. They issued a “hold” rating and a $79.00 price target on the stock. Evercore ISI upgraded PerkinElmer from an “in-line” rating to an “outperform” rating and upped their price target for the company from $89.00 to $114.00 in a research report on Thursday, January 2nd. Citigroup started coverage on PerkinElmer in a research report on Monday, January 6th. They issued a “neutral” rating and a $100.00 price target on the stock. Stifel Nicolaus reiterated a “buy” rating on shares of PerkinElmer in a research report on Thursday, November 21st. Finally, Bank of America upgraded PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 price target on the stock in a research report on Thursday, September 26th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $84.79.

In other news, insider Andrew Okun sold 11,984 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $94.12, for a total value of $1,127,934.08. Also, Director Pascale Witz sold 1,043 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $90.67, for a total value of $94,568.81. Following the completion of the sale, the director now directly owns 2,446 shares of the company’s stock, valued at $221,778.82. The disclosure for this sale can be found here. Corporate insiders own 1.80% of the company’s stock.

Shares of PerkinElmer stock traded down $0.10 on Friday, hitting $99.29. 18,206 shares of the company’s stock traded hands, compared to its average volume of 465,175. PerkinElmer, Inc. has a one year low of $78.35 and a one year high of $103.00. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.30 and a quick ratio of 0.97. The company has a fifty day moving average of $97.55 and a two-hundred day moving average of $89.64. The company has a market capitalization of $11.20 billion, a price-to-earnings ratio of 47.43, a price-to-earnings-growth ratio of 1.74 and a beta of 1.30.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.05. The business had revenue of $706.92 million for the quarter, compared to analyst estimates of $722.69 million. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The company’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.90 earnings per share. Equities research analysts anticipate that PerkinElmer, Inc. will post 4.08 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Stockholders of record on Friday, April 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.28%. PerkinElmer’s dividend payout ratio (DPR) is presently 7.76%.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Featured Article: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.